false
0002040475
0002040475
2026-03-06
2026-03-06
0002040475
DMIIU:UnitsEachConsistingOfOneOrdinaryShare0.0001ParValueAndOneRightToReceiveOnetenthOfOneOrdinaryShareMember
2026-03-06
2026-03-06
0002040475
DMIIU:OrdinarySharesParValue0.0001PerShareMember
2026-03-06
2026-03-06
0002040475
DMIIU:RightsEachEntitlingHolderToReceiveOnetenthOfOneOrdinaryShareMember
2026-03-06
2026-03-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): March
6, 2026
Drugs Made In America Acquisition II Corp.
(Exact Name of Registrant as Specified in Charter)
| Cayman Islands |
|
001-42863 |
|
99-1815624 |
(State or Other Jurisdiction
of Incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
1 East Broward Boulevard, Suite 700
Fort Lauderdale, FL 33301
(Address of Principal Executive Offices) (Zip Code)
646-726-7074
(Registrant’s Telephone Number, Including Area
Code)
Not Applicable
(Former Name or Former Address, if Changed Since Last
Report)
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
Securities registered pursuant to Section 12(b)
of the Act:
| Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which registered |
| Units, each consisting of one ordinary share, $0.0001 par value, and one right to receive one-tenth of one ordinary share |
|
DMIIU |
|
The Nasdaq Stock Market LLC |
| Ordinary shares, par value $0.0001 per share |
|
DMII |
|
The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to receive one-tenth of one Ordinary Share |
|
DMIIR |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an
emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of
the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01. Other Events
As previously reported in
the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026, Drugs Made In America Acquisition II
Corp. (the “Company”) announced that, between the completion of its initial public offering on September 26, 2025 and December
31, 2025, the sponsor to the Company made certain improper withdrawals (the “Irregularities”) from the Company’s working
capital account.
As a result of the events
reported above, the board of directors of the Company immediately took action to confirm that the Irregularities did not extend to the
Company’s trust account (“Trust Account”), and as of today, March 6, 2026, the Company is confirming that approximately
$507,841,957 is the Trust Account.
SIGNATURE
Pursuant to the requirements of
the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: March 6, 2026
| |
DRUGS MADE IN AMERICA ACQUISITION II CORP. |
| |
|
|
| |
By: |
/s/ Roger Bendelac |
| |
|
Name: |
Roger Bendelac |
| |
|
Title: |
Chief Executive Officer |
